Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

Stopped Dompé decided to withdraw LDX0121 following an internal re-planning and an extensive review of the study design. At the time of withdrawal, no site had been activated and the drug had not been sent to investigators. No patients had been enrolled.

Conditions

• Type I Diabetes

Interventions

• DRUG: Ladarixin
• OTHER: Placebo

Sponsor

Dompé Farmaceutici S.p.A